This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2015 Dec;16(16):1574-6.

doi: 10.1016/S1470-2045(15)00360-5. Epub 2015 Oct 23.

DPD deficiency in patients treated with fluorouracil

Joseph Ciccolini¹

Affiliations

PMID: 26603944
DOI: 10.1016/S1470-2045(15)00360-5

Comment

DPD deficiency in patients treated with fluorouracil

Joseph Ciccolini. Lancet Oncol. 2015 Dec.

. 2015 Dec;16(16):1574-6.

doi: 10.1016/S1470-2045(15)00360-5. Epub 2015 Oct 23.

Author

Joseph Ciccolini¹

Affiliation

¹ Clinical Pharmacokinetics Laboratory, La Timone University Hospital of Marseille, 13385 Marseille, France. Electronic address: joseph.ciccolini@univ-amu.fr.

PMID: 26603944
DOI: 10.1016/S1470-2045(15)00360-5

No abstract available

PubMed Disclaimer

Comment on

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiadèr CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl Z, Kleiblova P, Schwab M, Zanger UM, Palles C, Tomlinson I, Gross E, van Kuilenburg AB, Punt CJ, Koopman M, Beijnen JH, Cats A, Schellens JH. Meulendijks D, et al. Lancet Oncol. 2015 Dec;16(16):1639-50. doi: 10.1016/S1470-2045(15)00286-7. Epub 2015 Oct 23. Lancet Oncol. 2015. PMID: 26603945

Similar articles

Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity.
Ticha I, Kleiblova P, Fidlerova J, Novotny J, Pohlreich P, Kleibl Z. Ticha I, et al. Cancer Chemother Pharmacol. 2009 Aug;64(3):615-8. doi: 10.1007/s00280-009-0970-4. Epub 2009 Mar 14. Cancer Chemother Pharmacol. 2009. PMID: 19288105
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
van Kuilenburg AB. van Kuilenburg AB. Eur J Cancer. 2004 May;40(7):939-50. doi: 10.1016/j.ejca.2003.12.004. Eur J Cancer. 2004. PMID: 15093568 Review.
Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?
Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C. Ciccolini J, et al. Clin Colorectal Cancer. 2010 Oct;9(4):224-8. doi: 10.3816/CCC.2010.n.033. Clin Colorectal Cancer. 2010. PMID: 20920994 Review.
Should DPD analysis be required prior to prescribing fluoropyrimidines?
Yen JL, McLeod HL. Yen JL, et al. Eur J Cancer. 2007 Apr;43(6):1011-6. doi: 10.1016/j.ejca.2007.01.030. Epub 2007 Mar 12. Eur J Cancer. 2007. PMID: 17350823 Review.
To perform genotyping of dihydropyrimidine dehydrogenase (DPD) before starting treatment with 5-fluorouracil or related medicines: really feasible?
Giuliani J, Bonetti A. Giuliani J, et al. Int J Colorectal Dis. 2021 Jan;36(1):197-198. doi: 10.1007/s00384-020-03754-0. Epub 2020 Sep 14. Int J Colorectal Dis. 2021. PMID: 32929530 No abstract available.

See all similar articles

Cited by

Lay understandings of drug-gene interactions: The right medication, the right dose, at the right time, but what are the right words?
Meagher KM, Stuttgen Finn K, Curtis SH, Borucki J, Beck AT, Cheema AW, Sharp RR. Meagher KM, et al. Clin Transl Sci. 2022 Mar;15(3):721-731. doi: 10.1111/cts.13193. Epub 2021 Nov 25. Clin Transl Sci. 2022. PMID: 34755460 Free PMC article.
Pharmacogenomics: time to rethink its role in precision medicine.
Willis JA, Vilar E. Willis JA, et al. Ann Oncol. 2018 Feb 1;29(2):293-295. doi: 10.1093/annonc/mdx780. Ann Oncol. 2018. PMID: 29236957 Free PMC article. No abstract available.
CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine.
Fanciullino R, Farnault L, Donnette M, Imbs DC, Roche C, Venton G, Berda-Haddad Y, Ivanov V, Ciccolini J, Ouafik L, Lacarelle B, Costello R. Fanciullino R, et al. Blood Adv. 2018 Mar 13;2(5):462-469. doi: 10.1182/bloodadvances.2017014126. Blood Adv. 2018. PMID: 29490977 Free PMC article.
Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a case report.
Mukherji D, Massih SA, Tfayli A, Kanso M, Faraj W. Mukherji D, et al. J Med Case Rep. 2019 Mar 22;13(1):76. doi: 10.1186/s13256-019-2013-z. J Med Case Rep. 2019. PMID: 30898145 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information